Literature DB >> 25207821

Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group.

Risa Teshiba1, Shinya Kawano, Larry L Wang, Lejian He, Arlene Naranjo, Wendy B London, Robert C Seeger, Julie M Gastier-Foster, A Thomas Look, Michael D Hogarty, Susan L Cohn, John M Maris, Julie R Park, Hiroyuki Shimada.   

Abstract

Prognostic effects of Mitosis-Karyorrhexis Index (MKI) used in the International Neuroblastoma Pathology Classification (INPC) are age-dependent. A total of 4,282 neuroblastomas reviewed at the Children's Oncology Group Neuroblastoma Pathology Reference Laboratory (8/1/2001-3/31/2012) included 2,365 low-MKI (L-MKI), 1,068 intermediate-MKI (I-MKI), and 849 high-MKI (H-MKI) tumors. Cox proportional hazards models were fit to determine age cut-offs at which the relative risk of event/death was maximized in each MKI class. Backward-selected Cox models were fit to determine the prognostic strength of the age cut-offs for survival in the presence of other prognostic factors. The age cut-offs used in the INPC for L-MKI tumors (<60 months, n  =  2,710, 84.0% ± 1.0% event-free survival [EFS], 93.8 ± 0.7% overall survival [OS] vs ≥60 months, n  =  195, 49.8% ± 4.6% EFS, 71.7% ± 4.1% OS; P < 0.0001) and I-MKI tumors (<18 months, n  =  568, 83.8% ± 2% EFS, 93.7% ± 1.3% OS vs ≥18 months, n  =  500, 51.4% ± 2.9% EFS, 66.7% ± 2.7% OS; P < 0.0001) were within the effective range for distinguishing prognostic groups. As for H-MKI tumors (no cut-off age in the INPC, 51.0% ± 2.2% EFS, 64.4% ± 2.1% OS), a new cut-off of 3-4 months was suggested (<4 months, n  =  38, 82.3% ± 8.4% EFS, 81.8% ± 8.5% OS vs ≥4 months, n  =  811, 49.6% ± 2.2% EFS, 63.7% ± 2.1% OS, P  =  0.0034 and 0.0437, respectively). Multivariate analyses revealed that cut-offs of 60 and 18 months for L-MKI and I-MKI tumors, respectively, were independently prognostic. However, the cut-off of 4 months for H-MKI tumors did not reach statistical significance in the presence of other factors. The age cut-offs for MKI classes (60 months for L-MKI, 18 months for I-MKI, no cut-off for H-MKI) in the current INPC are reasonable and effective for distinguishing prognostic groups with increased risk of event/death for older patients.

Entities:  

Keywords:  International Neuroblastoma Pathology Classification; age cut-off; mitosis-karyorrhexis index; neuroblastoma; prognosis

Mesh:

Substances:

Year:  2014        PMID: 25207821      PMCID: PMC4340697          DOI: 10.2350/14-06-1505-OA.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  31 in total

Review 1.  The Max network gone mad.

Authors:  T A Baudino; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.

Authors:  G M Brodeur; R C Seeger; A Barrett; F Berthold; R P Castleberry; G D'Angio; B De Bernardi; A E Evans; M Favrot; A I Freeman
Journal:  J Clin Oncol       Date:  1988-12       Impact factor: 44.544

3.  Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Authors:  S Goto; S Umehara; R B Gerbing; D O Stram; G M Brodeur; R C Seeger; J N Lukens; K K Matthay; H Shimada
Journal:  Cancer       Date:  2001-11-15       Impact factor: 6.860

4.  International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Authors:  H Shimada; S Umehara; Y Monobe; Y Hachitanda; A Nakagawa; S Goto; R B Gerbing; D O Stram; J N Lukens; K K Matthay
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

5.  N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation.

Authors:  Paul S Knoepfler; Pei Feng Cheng; Robert N Eisenman
Journal:  Genes Dev       Date:  2002-10-15       Impact factor: 11.361

6.  Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular.

Authors:  S Umehara; A Nakagawa; K K Matthay; J N Lukens; R C Seeger; D O Stram; R B Gerbing; H Shimada
Journal:  Cancer       Date:  2000-09-01       Impact factor: 6.860

7.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

Authors:  R C Seeger; G M Brodeur; H Sather; A Dalton; S E Siegel; K Y Wong; D Hammond
Journal:  N Engl J Med       Date:  1985-10-31       Impact factor: 91.245

8.  Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas.

Authors:  H Shimada; J Chatten; W A Newton; N Sachs; A B Hamoudi; T Chiba; H B Marsden; K Misugi
Journal:  J Natl Cancer Inst       Date:  1984-08       Impact factor: 13.506

9.  Prognostic factors in neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis.

Authors:  B R Oppedal; I Storm-Mathisen; S O Lie; P Brandtzaeg
Journal:  Cancer       Date:  1988-08-15       Impact factor: 6.860

10.  N-myc proto-oncogene expression during organogenesis in the developing mouse as revealed by in situ hybridization.

Authors:  G Mugrauer; F W Alt; P Ekblom
Journal:  J Cell Biol       Date:  1988-10       Impact factor: 10.539

View more
  16 in total

1.  Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

Authors:  Kevin Campbell; Julie M Gastier-Foster; Meegan Mann; Arlene H Naranjo; Collin Van Ryn; Rochelle Bagatell; Katherine K Matthay; Wendy B London; Meredith S Irwin; Hiroyuki Shimada; M Meaghan Granger; Michael D Hogarty; Julie R Park; Steven G DuBois
Journal:  Cancer       Date:  2017-07-11       Impact factor: 6.860

2.  MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

Authors:  Steven G DuBois; Rajen Mody; Arlene Naranjo; Collin Van Ryn; Douglas Russ; Derek Oldridge; Susan Kreissman; David L Baker; Marguerite Parisi; Barry L Shulkin; Harrison Bai; Sharon J Diskin; Vandana Batra; John M Maris; Julie R Park; Katherine K Matthay; Gregory Yanik
Journal:  Pediatr Blood Cancer       Date:  2017-04-06       Impact factor: 3.167

3.  High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas.

Authors:  Pramila Ramani; Scott Taylor; Elizabeth Miller; Emile Sowa-Avugrah; Margaret T May
Journal:  J Histochem Cytochem       Date:  2015-02-23       Impact factor: 2.479

4.  Estimating the time of skeletal muscle contusion based on the spatial distribution of neutrophils: a practical approach to forensic problems.

Authors:  Qiu-Xiang Du; Liang Wang; Dan Li; Jia-Jia Niu; Xu-Dong Zhang; Jun-Hong Sun
Journal:  Int J Legal Med       Date:  2021-09-13       Impact factor: 2.686

5.  Analysis of sensitivity and specificity: precise recognition of neutrophils during regeneration of contused skeletal muscle in rats.

Authors:  Jiajia Niu; Guoshuai An; Zhen Gu; Peng Li; Qiqing Liu; Rufeng Bai; Junhong Sun; Qiuxiang Du
Journal:  Forensic Sci Res       Date:  2020-03-19

Review 6.  Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

Authors:  Wendy B London; Rochelle Bagatell; Brenda J Weigel; Elizabeth Fox; Dongjing Guo; Collin Van Ryn; Arlene Naranjo; Julie R Park
Journal:  Cancer       Date:  2017-09-08       Impact factor: 6.860

7.  Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.

Authors:  Daria Thompson; Kieuhoa T Vo; Wendy B London; Matthias Fischer; Peter F Ambros; Akira Nakagawara; Garrett M Brodeur; Katherine K Matthay; Steven G DuBois
Journal:  Cancer       Date:  2015-12-28       Impact factor: 6.860

8.  Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis.

Authors:  Kumiko Uryu; Riki Nishimura; Keisuke Kataoka; Yusuke Sato; Atsuko Nakazawa; Hiromichi Suzuki; Kenichi Yoshida; Masafumi Seki; Mitsuteru Hiwatari; Tomoya Isobe; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Katsuyoshi Koh; Ryoji Hanada; Akira Oka; Yasuhide Hayashi; Miki Ohira; Takehiko Kamijo; Hiroki Nagase; Tetsuya Takimoto; Tatsuro Tajiri; Akira Nakagawara; Seishi Ogawa; Junko Takita
Journal:  Oncotarget       Date:  2017-11-18

9.  Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.

Authors:  Anat Erdreich-Epstein; Donald L Durden; Alok R Singh; Shweta Joshi; Francisco M Vega; Pinzheng Guo; Jingying Xu; Susan Groshen; Wei Ye; Melissa Millard; Mihaela Campan; Guillermo Morales; Joseph R Garlich; Peter W Laird; Robert C Seeger; Hiroyuki Shimada
Journal:  Oncotarget       Date:  2016-11-18

10.  Prognostic Value of c-MYC Expression in Patients with Peripheral Neuroblastic Tumors.

Authors:  Feng Zhang; Zhuo Tian; Tinghong Li; Xianjun Hu; Jin Zhu
Journal:  Int J Gen Med       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.